Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre

Abstract

PASI 90 response at 6 months was the only independent variable predicting drug survival on multivariate analysis. Infections, including de novo infection by Mycobacterium tuberculosis, accounted for seven serious AEs.

Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary

“…Biological therapy-naïve status was shown to be a positive predictor for persistence in psoriasis by Gniadecki et al, and, similarly, Lopez-Ferrer could also demonstrate reduction of adalimumab drug survival in patients with prior exposure to another TNF-alpha inhibitor. On the other hand, there are studies which similar to the current study did not find previous biological therapy usage as a negative predictor of persistence (11,16,20,21,23). Although concomitant MTX usage has been shown to be associated with a better persistence of biologicals in rheumatological settings, there is no conclusive evidence in psoriasis about additional MTX as a positive predictor (24,25).…”

Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting

“…The unit costs were D 496.61 for adalimumab (40 mg syringe), 21 The cost per patient per year was calculated for each treatment regimen and drug.…”

Combining biologics with methotrexate in psoriasis: a systematic review

“…same in psoriasis because of their inherent higher risk of non-alcoholic fatty liver disease 11,12 . In view of the results in Table 1, a MTX dose ranging from 5-15 mg/week may be considered for improving efficacy and drug survival while limiting the risk of hepatotoxicity 6,13,14 We conclude that the available evidence on combination treatment of biologics and MTX in psoriasis is currently not sufficient to propose an amendment of the current treatment guidelines. However, our findings do support the initiation of adequately powered RCTs to compare biologic monotherapy versus MTX combination therapy in psoriasis.…”